معرفی
Kilian Huber is an Associate Professor and Senior Group Leader at the University of Oxford, jointly based at the Nuffield Department of Medicine and its Centre for Medicines Discovery. He also leads the Huber Laboratory within the ChemBioHub and Target Discovery Institute (TDI), where he pioneers chemical-biology approaches to discover and validate new drug targets.
Education & Career:
- Current: Associate Professor, University of Oxford
- Group Leader, Centre for Medicines Discovery & Target Discovery Institute
Research Interests:
Dr Huber integrates chemistry, structural biology, proteomics and functional genomics to create potent and selective chemical probes that illuminate the role of proteins in disease. His laboratory is renowned for:
- Protein kinase structural biology – having solved >60 novel kinase crystal structures.
- Epigenetic reader domains – developing first-in-class inhibitors for bromodomains that recognise acetyl-lysine marks.
- Chemical proteomics – employing chemoproteomics and thermal-stability profiling to map cellular targets of small molecules in native proteomes.
- High-throughput technologies – including NanoBRET target-engagement assays, AlphaScreen, BLI, ITC and fragment-based crystallography.
Research Themes & Technologies:
Current efforts span cancer, neurodegeneration, inflammatory disorders and viral infections, with particular emphasis on:
- Structure-guided design of selective kinase and epigenetic inhibitors.
- Systems-level phenomic and chemoproteomic screening to uncover novel biology.
- Open-science initiatives such as the EUbOPEN consortium that aims to deliver chemical probes for the entire human proteome by 2035.
Collaborations & Resources:
The Huber group operates state-of-the-art platforms for high-throughput crystallography, chemical library screening and target deconvolution in close partnership with the Structural Genomics Consortium, ARUK Oxford Drug Discovery Institute and multiple industry partners.
Recent Publications Snapshot:
Work published in 2024-2025 addresses anti-ageing effects of bisphosphonates, ALS drug-repurposing strategies, circadian-immune pathway modulation via BMAL1, kinase inhibitor selectivity, SARS-CoV-2 antivirals, and open-access chemical probe generation, reflecting a vibrant pipeline from fundamental discovery toward translational impact.
